#summit-therapeutics
Latest news and interesting information about summit-therapeutics.
Why is Summit Therapeutics stock sliding?
Summit Therapeutics stock drops 5.3% after Bernstein and H.C. Wainwright issue bearish ratings. Analyst concerns over trial failures drive sell-off.
Summit Therapeutics Analysis: Cantor Fitzgerald Backs Overweight
Cantor Fitzgerald reiterates Overweight on Summit Therapeutics. HARMONi-3 trial miss and analyst views covered by Bond.az.
Summit Therapeutics downgraded to neutral
H.C. Wainwright downgrades Summit Therapeutics to Neutral due to competitive pressure from Merck.
...